JP2020507332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507332A5 JP2020507332A5 JP2019544614A JP2019544614A JP2020507332A5 JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5 JP 2019544614 A JP2019544614 A JP 2019544614A JP 2019544614 A JP2019544614 A JP 2019544614A JP 2020507332 A5 JP2020507332 A5 JP 2020507332A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- protein
- pharmaceutical composition
- composition according
- salmonella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023133276A JP2023160838A (ja) | 2017-02-17 | 2023-08-18 | 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17156718 | 2017-02-17 | ||
| EP17156718.3 | 2017-02-17 | ||
| PCT/EP2018/053918 WO2018149982A1 (en) | 2017-02-17 | 2018-02-16 | Novel vegfr-2 targeting immunotherapy approach |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133276A Division JP2023160838A (ja) | 2017-02-17 | 2023-08-18 | 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507332A JP2020507332A (ja) | 2020-03-12 |
| JP2020507332A5 true JP2020507332A5 (OSRAM) | 2021-03-25 |
| JP7712060B2 JP7712060B2 (ja) | 2025-07-23 |
Family
ID=58094260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019544614A Active JP7712060B2 (ja) | 2017-02-17 | 2018-02-16 | 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ |
| JP2023133276A Withdrawn JP2023160838A (ja) | 2017-02-17 | 2023-08-18 | 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133276A Withdrawn JP2023160838A (ja) | 2017-02-17 | 2023-08-18 | 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10980868B2 (OSRAM) |
| EP (1) | EP3583200A1 (OSRAM) |
| JP (2) | JP7712060B2 (OSRAM) |
| KR (2) | KR20190117603A (OSRAM) |
| CN (1) | CN110291187A (OSRAM) |
| AU (1) | AU2018222777B9 (OSRAM) |
| BR (1) | BR112019016925A2 (OSRAM) |
| CA (1) | CA3050833A1 (OSRAM) |
| IL (1) | IL268186A (OSRAM) |
| MX (1) | MX2019009724A (OSRAM) |
| RU (1) | RU2019125436A (OSRAM) |
| SG (1) | SG11201907391SA (OSRAM) |
| WO (1) | WO2018149982A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046631T2 (hu) * | 2015-06-18 | 2020-03-30 | Vaximm Ag | VEGFR-2 targetáló DNS vakcina kombinációs terápiára |
| WO2020049036A1 (en) * | 2018-09-05 | 2020-03-12 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| CN113527509B (zh) * | 2020-04-17 | 2023-09-26 | 深圳华大生命科学研究院 | 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| WO2013091898A1 (en) | 2011-12-22 | 2013-06-27 | Vaximm Ag | Method for producing high yield attenuated salmonella strains |
| EP3603664A1 (en) * | 2012-07-05 | 2020-02-05 | Vaximm AG | Dna vaccine for use in pancreatic cancer patients |
| SG11201508521SA (en) * | 2013-04-25 | 2015-11-27 | Vaximm Ag | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| HUE045567T2 (hu) * | 2013-12-18 | 2020-01-28 | Vaximm Gmbh | MSLN-t célzó DNS vakcina rák immunterápiához |
| WO2015142875A1 (en) * | 2014-03-17 | 2015-09-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods using modified salmonella |
| HUE046631T2 (hu) * | 2015-06-18 | 2020-03-30 | Vaximm Ag | VEGFR-2 targetáló DNS vakcina kombinációs terápiára |
| JP7098599B2 (ja) | 2016-07-13 | 2022-07-11 | エンエーセー オンコイミュニティ アクスイェ セルスカプ | 癌免疫療法用のｄｎａワクチンの製造方法 |
-
2018
- 2018-02-16 RU RU2019125436A patent/RU2019125436A/ru not_active Application Discontinuation
- 2018-02-16 AU AU2018222777A patent/AU2018222777B9/en active Active
- 2018-02-16 US US16/486,425 patent/US10980868B2/en active Active
- 2018-02-16 SG SG11201907391SA patent/SG11201907391SA/en unknown
- 2018-02-16 CA CA3050833A patent/CA3050833A1/en active Pending
- 2018-02-16 EP EP18704568.7A patent/EP3583200A1/en active Pending
- 2018-02-16 CN CN201880012318.8A patent/CN110291187A/zh active Pending
- 2018-02-16 KR KR1020197026398A patent/KR20190117603A/ko not_active Ceased
- 2018-02-16 KR KR1020247035606A patent/KR20240170928A/ko active Pending
- 2018-02-16 BR BR112019016925-3A patent/BR112019016925A2/pt not_active Application Discontinuation
- 2018-02-16 JP JP2019544614A patent/JP7712060B2/ja active Active
- 2018-02-16 WO PCT/EP2018/053918 patent/WO2018149982A1/en not_active Ceased
- 2018-02-16 MX MX2019009724A patent/MX2019009724A/es unknown
-
2019
- 2019-07-21 IL IL268186A patent/IL268186A/en unknown
-
2023
- 2023-08-18 JP JP2023133276A patent/JP2023160838A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511139A5 (OSRAM) | ||
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| Weichselbaum | The 46th David A. Karnofsky Memorial Award lecture: oligometastasis—from conception to treatment | |
| JP6945301B2 (ja) | Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン | |
| RU2016129044A (ru) | Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака | |
| Fan et al. | Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity | |
| RU2015103758A (ru) | Днк-вакцина для применения у пациентов с раком поджелудочной железы | |
| US10987432B2 (en) | Therapeutic delivery and expression system, methods and uses thereof | |
| Kang et al. | Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects | |
| Mei et al. | Combining DNA vaccine and AIDA-1 in attenuated Salmonella activates tumor-specific CD4+ and CD8+ T-cell responses | |
| JP2018517419A5 (OSRAM) | ||
| Zhao et al. | Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response | |
| JP2020507332A5 (OSRAM) | ||
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| CN114592010A (zh) | NK-CAR-MbIL-15细胞及其制备方法和应用 | |
| BR112021001117A2 (pt) | células cancerígenas modificadas, composição farmacêutica, linha celular, métodos para fazer células cancerígenas modificadas e para estimular uma resposta imune, vetor de expressão isolado ou combinação de vetores de expressão isolados, e, uma ou mais células cancerígenas modificadas | |
| CN110408634B (zh) | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 | |
| Menezes et al. | Prospects of gene therapy to treat melanoma | |
| JP2023160838A (ja) | 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ | |
| Jia et al. | The future of cancer vaccines against colorectal cancer | |
| Kim et al. | Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism | |
| RU2019112977A (ru) | Днк-вакцина, нацеленная на wt1, для комбинированной терапии | |
| Bella et al. | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis | |
| Sun et al. | Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy |